Company Overview and News

481
Your Daily Pharma Scoop: Tetraphase Positive Data, MediWound In Phase 3, Allergan Moves Up

2018-06-13 seekingalpha
Tetraphase Pharma (TTPH) has a PDUFA on August 28 for its lead drug candidate ERAVACYCLINE in one indication - cIAI - complicated intra-abdominal infections. This PDUFA is based on an NDA filed on Feb 27 - the 6-month duration comes from a Fast Track designation; they also have a Qualified Infectious Disease Product (‘QIDP) for the drug candidate.
NTLA MKGAF OPK RCUS CORV ENL AQXP CUR EDIT ALXN AGN ADXS PFNX GTBP AMGN VTGN CRSP MDWD LLY SNY VICL LIVN MKGAY LIVN ENDP

190
Advaxis Makes A Bold Strategic Move, Was There A Major Logical Reason Behind It?

2018-06-11 seekingalpha
Advaxis announces restructuring with 24% of the workforce being cut and a change of the programs in its pipeline.
AMGN ADXS

472
Has A New Advaxis Awakened Out Of The Doldrums?

2018-06-08 seekingalpha
Advaxis has reformed its management team, with a new CEO and CFO, and a CMO after a long search.
AZN AMGN ADXS AVEO AZN

128
Advaxis Inc. (ADXS) CEO Ken Berlin on Q2 2018 Results - Earnings Call Transcript

2018-06-07 seekingalpha
Welcome to the Advaxis Conference Call. At this time, all participants are in a listen-only mode. Following management’s prepared remarks, we’ll hold a Q&A session [Operator Instructions]. As a reminder, this conference is being recorded, June 07, 2018.
ADXSW ADXS

351
This One Study Could Radically Change The Cancer Immunotherapy Market

2018-06-07 seekingalpha
The cause is speculated to be that antibiotics clear the gut of bacteria, which decreases the amount of circulating immune cells, which in turn lessens the effect of immunotherapy.
SGEN MRK TSRO AMGN BMYMP ADXS BLUE CELG BLUE SNDX BMY

135
OncoSec: Will CEO O'Connor Oversee Another Advaxis-Like Run?

2018-05-31 seekingalpha
We look back at what has held OncoSec in place and look forward to what may propel it.
ADXS ONCS

185
The No BS Report, Week 12: Living In Yawnsville With Little But Gains

2018-05-06 seekingalpha
In many cases, the trading remains flat as we continue a relatively quiet period for the holdings in the No BS plan.
NVCR GERN ADXS FMI PGNX

165
3 Things In Biotech, May 3: Bristol Bows Out Of IDO, And Two Biotechs Look To Investigate Novel Immunotherapies

2018-05-04 seekingalpha
Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we're talking about! Here is some more information if you're curious.
NLNK ADRO ADXS INCY

188
The No BS Report, Week 11: Rising Tides And Sinking Ships?

2018-04-29 seekingalpha
Author's note: As always, I'm happy to answer questions in the comments below, but you can get direct access to me in the Total Pharma Tracker chatroom if you want to discuss in further detail! Right now you can get a no-obligation free trial to the service for two weeks.
NVCR GERN ADXS MRK FMI PGNX

196
The No BS Plan Report, Week 10: Where The Reliable Falter

2018-04-22 seekingalpha
Mostly the stocks continue to hold, too high or low to reach targets, but this could change quickly.
NVCR GERN ADXS JNJ FMI BMY PGNX

ADXS : Advaxis Stock Analysis and Research Report

2017-10-31 - Asif

Advaxis is a late-stage biotechnology company focused on the discovery, development and commercialization of proprietary Lm-based antigen delivery products with the lead program in Phase 3 development. These immunotherapies are based on a platform technology that utilizes live attenuated Listeria monocytogenes bioengineered to secrete antigen/adjuvant fusion proteins. These Lm-based strains are believed to be a significant advancement in immunotherapy as they integrate multiple functions into a single immunotherapy as they access and direct antigen presenting cells to stimulate anti-tumor T-cell immunity, stimulate and activate the immune system with the equivalent of multiple adjuvants, and simultaneously reduce tumor protection in the tumor microenvironment to enable the T-cells to eliminate tumors. Advaxis will continue to invest in its core clinical franchises and will also remain opportunistic based on Investigator Sponsored Trials (“ISTs”) as well as licensing opportunities. ...

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

Silicon Investor Message Boards

This table lists all message boards related to ADXS / Advaxis, Inc. on message board site Silicon Investor.

ADXS - Advaxis, Inc. (Bulls Board)
CUSIP: 007624208